Exclusive: Gene editing startup Seamless hires ex-Homology leader, doubles seed round

A small Ger­man biotech at­tempt­ing to crack in­to the gene edit­ing field with an evolved ap­proach to a decades-old re­search in­ter­est has nabbed for­mer Ho­mol­o­gy Med­i­cines ex­ec­u­tive Al­bert Sey­mour as CEO.

Seam­less Ther­a­peu­tics, which emerged last year with about $12.5 mil­lion, is ex­pand­ing in­to the Boston area and tack­ing on an­oth­er $12.5 mil­lion led by For­bion and Welling­ton Part­ners, the biotech told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.